Table 1 Clinical and molecular characteristics of NRASmut AML.
From: Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia
Characteristics | Median (interquartile range) or N (%) |
|---|---|
Gender (male) | 76 (50%) |
Age (years) | 44 (30–55) |
Age ≥ 60 years | 25 (16%) |
M3 | 12 (8%) |
NRAS type | |
G12/G13 | 120 (79%) |
Q61 | 26 (17%) |
Mix | 5 (3%) |
NRAS VAF (%) | 15 (6–33) |
NRAS VAF (≥ 15%) | 76(50%) |
WBC counts (× 109/L) | 31 (9–75) |
WBC counts (≥ 100 × 109/L) | 27 (18%) |
HGB counts (g/L) | 75 (63–89) |
HGB counts (≥ 110 g/L) | 15 (10%) |
PLT counts (× 109/L) | 31 (15–71) |
PLT counts (≥ 100 × 109/L) | 20 (13%) |
BM blasts (%) | 59 (36–85) |
BM blasts (≥ 80%) | 45 (30%) |
Fusion genes (N = 135) | |
AML1-ETO | 16 (12%) |
MYH11-CBFβ | 15 (11%) |
MLL | 7 (5) |
BCR-ABL | 2 (1) |
SET-CAN | 1 (1) |
NUP98 | 1 (1) |
DEK-CAN | 1 (1) |
AML-EVI1 | 1 (1) |
AML-MTG1 | 1 (1) |
Risk group | |
Good | 41 (27%) |
Intermediate | 64 (42%) |
Poor | 47 (31%) |
Number of co-mutations (≥ 3) | 35 (23%) |
Allo-HSCT | 24 (16%) |
Non-CR | 36 (24%) |
Death | 61 (40%) |
